ncRNA basic information
ncRNA ID: MI0000786
ncRNA Database: miRBase
ncRNA Name: miR-378
ncRNA Type: miRNA
ncRNA Expression: up-regulated
ncRNA Method: RT-PCR
ncRNA Target Gene: NA
ncRNA Pathway: NA
Evidence (ncRNA-drug): validated
drug basic information
Drug ID: DB00515 (APRD00359)
Drug Name: Cisplatin
Drug Method: The objectives of the study were to determine the role of miR-378 in the sensitivity of lung adenocarcinoma cells to cisplatin (cDDP) and its working mechanism. With TargetScan and luciferase assay, miR-378 was found to directly target sCLU. miR-378 and sCLU were regulated in A549/cDDP and Anip973/cDDP cells to investigate the effect of miR-378 on the sensitivity and apoptotic effects of cDDP. The effect of miR-378 upregulation on tumor growth was analyzed in a nude mouse xenograft model. The correlation between miR-378 and chemoresistance was tested in patient samples. We found that upregulation of miR-378 in A549/cDDP and Anip973/cDDP cells significantly down-regulated sCLU expression, and sensitized these cells to cDDP. miR-378 overexpression inhibited tumor growth and sCLU expression in a xenograft animal model. Analysis of human lung adenocarcinoma tissues revealed that the cDDP sensitive group expressed higher levels of miR-378 and lower levels of sCLU. miR-378 and sCLU were negatively correlated.
Drug Response: sensitive
Cancer basic information
Cancer: lung adenocarcinoma
Tissue/Cell: cell line ((A549, Anip973, A549/cDDP, Anip973/cDDP)
Other information
Title: miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin.
Journal: Sci Rep
Published: 2016
PubMed ID: 26781643